SCHEMBL2480655

SCHEMBL2480655

CS(=O)(=O)C1CCN(c2ccc(Nc3cc(NCc4c(F)cccc4F)c(C(N)=O)cn3)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 8/20 0.53
JAK3 P52333 8/20 0.48
JAK2 O60674 4/20 0.46
JAK1 P23458 4/20 0.46
IRAK4 Q9NWZ3 3/20 0.46
TYK2 P29597 2/20 0.46
SYK P43405 4/20 0.43
BRD4 O60885 1/20 0.43
CHEK1 O14757 1/20 0.43
NUAK1 O60285 1/20 0.43
CSF1R P07333 1/20 0.43
RET P07949 1/20 0.43
FLT4 P35916 1/20 0.43
FLT3 P36888 1/20 0.43
RPS6KA3 P51812 1/20 0.43
MAPK10 P53779 1/20 0.43
MAP3K9 P80192 1/20 0.43
ITK Q08881 1/20 0.43
MAP4K2 Q12851 1/20 0.43
STK4 Q13043 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2479283 0.88 STAT6 (0.54) STAT6JAK3JAK2JAK1IRAK4
SCHEMBL12322720 0.87 STAT6 (0.60) STAT6JAK3JAK2JAK1IRAK4
SCHEMBL12322726 0.87 STAT6 (0.58) STAT6JAK3JAK2JAK1IRAK4
SCHEMBL2480596 0.86 STAT6 (0.71) STAT6JAK3JAK2JAK1IRAK4
SCHEMBL2482332 0.85 STAT6 (0.58) STAT6JAK3JAK2JAK1IRAK4
SCHEMBL2507016 0.85 STAT6 (0.53) STAT6JAK3JAK2JAK1IRAK4
SCHEMBL2482474 0.84 STAT6 (0.55) STAT6JAK3JAK2JAK1IRAK4
SCHEMBL12301522 0.83 STAT6 (0.54) STAT6JAK3JAK2JAK1IRAK4
SCHEMBL2510104 0.83 STAT6 (0.53) STAT6JAK3JAK2JAK1IRAK4
SCHEMBL2480814 0.82 STAT6 (0.55) STAT6JAK3JAK2JAK1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP claimed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US claimed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA STAT6 8/4885JAK3 1/4885JAK2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.